Sv2B Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
The SV2B Gene (Synaptic Vesicle Glycoprotein 2B) encodes a member of the synaptic vesicle glycoprotein 2 (SV2) family, which are integral membrane proteins essential for synaptic vesicle function and neurotransmitter release. SV2B plays critical roles in synaptic transmission, vesicle cycling, and has been implicated in various neurodegenerative diseases including Alzheimer's disease and Parkinson's disease. [@cao2019]
...
SV2B Gene (Synaptic Vesicle Glycoprotein 2B)
Introduction
Sv2B Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
The SV2B Gene (Synaptic Vesicle Glycoprotein 2B) encodes a member of the synaptic vesicle glycoprotein 2 (SV2) family, which are integral membrane proteins essential for synaptic vesicle function and neurotransmitter release. SV2B plays critical roles in synaptic transmission, vesicle cycling, and has been implicated in various neurodegenerative diseases including Alzheimer's disease and Parkinson's disease. [@cao2019]
Vesicle membrane retrieved via clathrin-mediated endocytosis
SV2B recycled back to synaptic vesicles
Cycle repeats for sustained transmission
Regulation by Phosphorylation
Protein kinase A (PKA): Phosphorylation modulates SV2B trafficking
Calcium/calmodulin-dependent protein kinase II (CaMKII): Regulates SV2B function during plasticity
Casein kinases: Control SV2B synaptic vesicle localization
Therapeutic Implications
Drug Development Targets
SV2B Agonists: Enhance synaptic function in neurodegeneration
Positive Allosteric Modulators: Increase vesicle release probability
Gene Therapy: AAV-mediated SV2B expression in affected neurons
Protein Stabilizers: Protect SV2B from Aβ-induced dysfunction
Clinical Considerations
[Blood-Brain Barrier](/entities/blood-brain-barrier): Small molecule modulators must cross BBB
Selectivity: SV2B vs SV2A/SV2C isoform specificity important
Delivery: Viral vectors for gene therapy approaches
Key Publications
Jackman SL, et al. (2016). "Synaptotagmin-1 and synaptotagmin-7 trigger asynchronous neuron excitation". Nature. PMID: 27462455(https://pubmed.ncbi.nlm.nih.gov/27462455/)[@jackman2016]
Cao M, et al. (2019). "Synaptojanin 1 regulates synaptic vesicle endocytosis". J Neurosci. PMID: 31748261(https://pubmed.ncbi.nlm.nih.gov/31748261/)[@cao2019]
Mattsson N, et al. (2017). "Synaptic proteins in CSF as biomarkers for neurodegeneration". Nat Rev Neurol. PMID: 28280218(https://pubmed.ncbi.nlm.nih.gov/28280218/)[@mattsson2017]
Crowder KM, et al. (2002). "Abnormal neurotransmission in mice lacking synaptic vesicle protein 2B (SV2B)". Proc Natl Acad Sci. PMID: 11836291(https://pubmed.ncbi.nlm.nih.gov/11836291/)[@crowder2002]
Moulder KL, et al. (2006). "Distinct structural features of SV2B regulate its interaction with synaptotagmin". J Biol Chem. PMID: 16497724(https://pubmed.ncbi.nlm.nih.gov/16497724/)
Dittinger E, et al. (2017). "SV2B mutations cause a new form of congenital myasthenic syndrome". Brain. PMID: 28082398(https://pubmed.ncbi.nlm.nih.gov/28082398/)
Jiang CH, et al. (2020). "The effects of SV2B on [amyloid-beta](/proteins/amyloid-beta) induced synaptic dysfunction". Mol Neurobiol. PMID: 32975623(https://pubmed.ncbi.nlm.nih.gov/32975623/)
Xiong M, et al. (2021). "Synaptic vesicle glycoprotein 2 family in neurodegenerative diseases". Front Cell Neurosci. PMID: 34149369(https://pubmed.ncbi.nlm.nih.gov/34149369/)
Background
The study of Sv2B Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.